Pfizer TUKYSA Receives FDA Approval for HER2+ Breast Cancer Maintenance Treatment

The U.S. Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a maintenance therapy for adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. This approval establishes a new chemotherapy-free maintenance option that allows eligible patients to delay disease progression without continuing taxane chemotherapy.

Key Clinical Trial Results (HER2CLIMB-05)

The approval is backed by data from the Phase III HER2CLIMB-05 trial, which enrolled 654 patients who completed four to eight cycles of induction therapy without disease progression. Key findings include:

Progression-Free Survival (PFS): Patients treated with TUKYSA, trastuzumab, and pertuzumab achieved a median PFS of 24.9 months, compared to 16.3 months in the placebo combination group—marking an 8.6-month improvement.
Risk Reduction: The regimen reduced the risk of disease progression or death by 35.9%, with a hazard ratio of 0.64 and a p-value of less than 0.0001.

Mechanism of Action & Safety Profile

Mechanism: TUKYSA is an oral tyrosine kinase inhibitor targeting HER2, while trastuzumab and pertuzumab are HER2-targeting monoclonal antibodies, working together across multiple pathways to inhibit tumor growth.
Safety & Warnings: The safety profile aligned generally with TUKYSA’s established data, though increased liver toxicity was observed. The FDA prescribing information includes a boxed warning for severe and potentially fatal hepatotoxicity, requiring liver function monitoring before and during treatment. Common adverse reactions include diarrhea, musculoskeletal pain, nausea, fatigue, rash, vomiting, and hepatotoxicity.